News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
174,880 Results
Type
Article (16973)
Company Profile (19)
Press Release (157888)
Section
Business (51864)
Career Advice (376)
Deals (8609)
Drug Delivery (47)
Drug Development (30581)
Employer Resources (38)
FDA (4724)
Job Trends (4556)
News (93774)
Policy (8400)
Tag
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (2)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Standard (1)
Academia (1025)
Accelerated approval (2)
Adcomms (12)
Allergies (29)
Alliances (12588)
ALS (37)
Alzheimer's disease (965)
Antibody-drug conjugate (ADC) (58)
Approvals (4703)
Artificial intelligence (86)
Autoimmune disease (10)
Automation (2)
Bankruptcy (61)
Best Places to Work (3706)
BIOSECURE Act (8)
Biosimilars (35)
Biotechnology (10)
Bladder cancer (36)
Brain cancer (14)
Breast cancer (150)
Cancer (1032)
Cardiovascular disease (76)
Career advice (319)
Career pathing (17)
CAR-T (77)
Cell therapy (175)
Cervical cancer (14)
Clinical research (24725)
Collaboration (276)
Compensation (35)
Complete response letters (5)
COVID-19 (1360)
CRISPR (17)
C-suite (91)
Cystic fibrosis (32)
Data (912)
Decentralized trials (1)
Denatured (2)
Depression (24)
Diabetes (104)
Diagnostics (2905)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (12)
Drug discovery (45)
Drug pricing (46)
Drug shortages (13)
Duchenne muscular dystrophy (40)
Earnings (20615)
Editorial (25)
Employer branding (5)
Employer resources (38)
Events (20047)
Executive appointments (279)
FDA (5162)
Featured Employer (4)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (2)
Funding (272)
Gene editing (54)
Generative AI (9)
Gene therapy (146)
GLP-1 (341)
Government (1495)
Grass and pollen (1)
Guidances (22)
Healthcare (5289)
Huntington's disease (10)
IgA nephropathy (15)
Immunology and inflammation (71)
Indications (13)
Infectious disease (1425)
Inflammatory bowel disease (44)
Inflation Reduction Act (3)
Influenza (16)
Intellectual property (34)
Interviews (80)
IPO (4214)
IRA (17)
Job creations (1041)
Job search strategy (257)
Kidney cancer (6)
Labor market (10)
Layoffs (227)
Leadership (7)
Legal (1435)
Liver cancer (30)
Lung cancer (164)
Lymphoma (70)
Machine learning (2)
Management (14)
Manufacturing (100)
MASH (34)
Medical device (3202)
Medtech (3204)
Mergers & acquisitions (4554)
Metabolic disorders (308)
Multiple sclerosis (39)
NASH (12)
Neurodegenerative disease (56)
Neuropsychiatric disorders (15)
Neuroscience (1209)
NextGen: Class of 2025 (1610)
Non-profit (1377)
Northern California (891)
Now hiring (1)
Obesity (181)
Opinion (125)
Ovarian cancer (33)
Pain (23)
Pancreatic cancer (46)
Parkinson's disease (73)
Partnered (5)
Patents (58)
Patient recruitment (33)
Peanut (18)
People (15832)
Pharmaceutical (5)
Pharmacy benefit managers (9)
Phase I (7780)
Phase II (11073)
Phase III (8748)
Pipeline (562)
Podcasts (15)
Policy (46)
Postmarket research (710)
Preclinical (2598)
Press Release (28)
Prostate cancer (42)
Psychedelics (13)
Radiopharmaceuticals (103)
Rare diseases (155)
Real estate (1405)
Recruiting (13)
Regulatory (6222)
Reports (10)
Research institute (979)
Resumes & cover letters (42)
Rett syndrome (1)
RNA editing (3)
RSV (23)
Schizophrenia (35)
Series A (60)
Series B (30)
Service/supplier (1)
Sickle cell disease (20)
Southern California (686)
Special edition (7)
Spinal muscular atrophy (85)
Sponsored (10)
Startups (1462)
Stomach cancer (6)
Supply chain (13)
Tariffs (7)
The Weekly (13)
United States (6802)
Vaccines (338)
Venture capitalists (27)
Webinars (8)
Weight loss (134)
Women's health (7)
Worklife (5)
Date
Today (37)
Last 7 days (243)
Last 30 days (982)
Last 365 days (11628)
2025 (2934)
2024 (11903)
2023 (13197)
2022 (16113)
2021 (16894)
2020 (15866)
2019 (12181)
2018 (9472)
2017 (9517)
2016 (8515)
2015 (9587)
2014 (6452)
2013 (4774)
2012 (5213)
2011 (5505)
2010 (4806)
Location
Africa (214)
Alabama (14)
Alaska (1)
Arizona (35)
Arkansas (3)
Asia (10977)
Australia (2213)
California (1882)
Canada (537)
China (186)
Colorado (71)
Connecticut (69)
Delaware (56)
Europe (26832)
Florida (231)
Georgia (45)
Idaho (7)
Illinois (147)
India (13)
Indiana (88)
Iowa (3)
Japan (59)
Kansas (36)
Kentucky (2)
Louisiana (2)
Maine (12)
Maryland (212)
Massachusetts (1416)
Michigan (47)
Minnesota (57)
Mississippi (1)
Missouri (18)
Montana (3)
Nebraska (8)
Nevada (12)
New Hampshire (35)
New Jersey (586)
New Mexico (12)
New York (593)
North Carolina (200)
Northern California (891)
Ohio (42)
Oklahoma (5)
Oregon (11)
Pennsylvania (369)
Puerto Rico (3)
Rhode Island (4)
South America (241)
South Carolina (2)
Southern California (686)
Tennessee (12)
Texas (342)
Utah (66)
Virginia (24)
Washington D.C. (17)
Washington State (169)
West Virginia (1)
Wisconsin (25)
174,880 Results for "earli".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Paving the Way for Early Esophageal Cancer Detection:
March 26, 2025
·
2 min read
Partnered
The Strategic Imperative: Why Early Potency Assay Development Makes or Breaks ATMP Success
Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP success but can cause costs and delays that lead to company closures.
December 9, 2024
·
7 min read
·
BioSpace Insights
Press Releases
LisenID Announces Collaboration with Mayo Clinic to Advance Early Cancer Diagnostics
April 1, 2025
·
1 min read
Obesity
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb studies and creates a “foothold” for AstraZeneca in the weight loss space.
November 5, 2024
·
3 min read
·
Tristan Manalac
Press Releases
LinusBio and The BRAIN Foundation Partner to Advance Biomarker-Supported Autism Diagnosis and Early Intervention
April 2, 2025
·
4 min read
Press Releases
University Hospitals Cleveland Medical Center Activates AI for Early Lung Cancer Identification
April 2, 2025
·
4 min read
Pipeline
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
March 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform
March 26, 2025
·
6 min read
1 of 17,488
Next
